Is BPC-157 Legal in Washington State? How to Access It Legally

Is BPC-157 approved or on a federal compounding list?

No FDA-approved drug contains BPC-157, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

BPC-157 appears in none of the three categories on FDA's list of bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), including category 1, the group FDA generally will not act against compounders for when conditions are met. It is also absent from FDA's separate list for outsourcing facilities (updated March 21, 2025) [2][3].

It was in category 2, the group of substances that may present significant safety risks, from September 2023 until April 22, 2026. It then moved to a nominated-but-withdrawn table because the groups that nominated it withdrew their nominations; the move was not a finding of safety [6][5]. That page still lists FDA's concerns, including risk of immunogenicity for certain routes of administration and peptide-related impurities and characterization problems [6].

What does the October 2026 HHS draft policy say?

HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy covering six peptides, BPC-157 among them, scheduled for Federal Register publication on October 30, 2026 [4][5].

Under the draft, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a listed peptide while FDA develops its list through rulemaking, if the conditions are met [4][5]. For BPC-157 those conditions include the acetate form only, a single active ingredient, subcutaneous, intramuscular, oral or topical use (nasal, rectal and intravenous are not listed), and a patient-specific prescription [5].

The notice says the draft does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [4][5].

What does this mean in Washington?

The federal documents describe FDA and HHS positions only. They do not address Washington pharmacy, medical practice or possession law, so they do not show whether the state permits compounding or dispensing of BPC-157. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [5].

How strong is the human evidence?

FDA's search of its adverse-event database through December 4, 2025 found three reports, all for injectable BPC-157, and FDA said it cannot tell whether the peptide caused them [1]. A 2026 systematic review found three human studies involving 30 patients. All had poor methodological quality, and the overall certainty of evidence was rated very low [8].